Literature DB >> 34731652

EMPEROR-Preserved: A promise fulfilled.

Deepak L Bhatt1, Subodh Verma2, Bertram Pitt3.   

Abstract

Heart failure with preserved ejection fraction (HFpEF) represents one of the greatest unmet needs in medicine. In the EMPEROR-Preserved trial, recently reported in the NEJM, the SGLT2 inhibitor empagliflozin reduced the primary outcome of heart failure hospitalizations and cardiovascular death by 21% in patients with HFpEF. This represents an important breakthrough in the war against heart failure.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34731652     DOI： 10.1016/j.cmet.2021.10.011

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  1 in total

1.  SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis.

Authors:  Danning Yang; Yu Zhang; Jie Yan; Ming Liu; Fengshuang An
Journal:  Front Cardiovasc Med       Date:  2022-09-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.